Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Street, Wuhan 430030, People’s Republic of China.
Nephrol Dial Transplant. 2011 Jun;26(6):1923-31. doi: 10.1093/ndt/gfq674. Epub 2010 Nov 16.
We wished to evaluate the clinical remission rate and long-term efficacy of tonsillectomy for patients with IgA nephropathy.
We searched a number of databases, including PubMed, CNKI, Wanfang and others, for clinical case-control studies of tonsillectomy in patients with IgA nephropathy. We then performed a meta-analysis of these studies. After evaluating total clinical remission rates, we compared the remission rates for specific treatments: tonsillectomy plus steroid pulse, tonsillectomy plus normal-dose steroid, and general treatment using neither tonsillectomy nor steroids. We also compared the rates of end-stage renal failure (ESRF) at last follow-up to estimate the long-term renal survival rate associated with each treatment.
Seven retrospective studies met the inclusion criteria and were included. These included a total of 858 patients, in which 534 underwent tonsillectomy and 324 did not. The total clinical remission rate was higher in the operative group, while the ESRF rate was higher in the non-operative group. The clinical remission rate in patients who underwent tonsillectomy remained higher than in the non-operative group at both 5- and 10-year follow-up. The clinical remission rate in patients who underwent tonsillectomy plus steroid pulse was higher than in those treated with steroid pulse alone, normal-dose steroids or general treatment alone (P < 0.05). However, the clinical remission rate of simple tonsillectomy was not higher than that of general treatment (P > 0.05).
Whereas neither tonsillectomy nor steroid treatment alone increased remission rates in patients with IgA nephropathy, tonsillectomy combined with either normal steroid or steroid pulse treatment resulted in higher remission rates with favourable long-term efficacy.
我们旨在评估扁桃体切除术治疗 IgA 肾病患者的临床缓解率和长期疗效。
我们检索了多个数据库,包括 PubMed、CNKI、万方等,以获取扁桃体切除术治疗 IgA 肾病的临床病例对照研究。然后,我们对这些研究进行了荟萃分析。在评估总临床缓解率后,我们比较了特定治疗的缓解率:扁桃体切除术加类固醇冲击治疗、扁桃体切除术加常规剂量类固醇治疗以及既不进行扁桃体切除术也不使用类固醇的常规治疗。我们还比较了最后一次随访时终末期肾衰竭(ESRF)的发生率,以估计每种治疗方法的长期肾脏存活率。
有 7 项回顾性研究符合纳入标准并被纳入。这些研究共纳入 858 例患者,其中 534 例接受了扁桃体切除术,324 例未接受。手术组的总临床缓解率较高,而未手术组的 ESRF 率较高。在 5 年和 10 年随访时,接受扁桃体切除术的患者的临床缓解率仍高于未手术组。接受扁桃体切除术加类固醇冲击治疗的患者的临床缓解率高于单独使用类固醇冲击治疗、常规剂量类固醇或常规治疗的患者(P<0.05)。然而,单纯扁桃体切除术的临床缓解率并不高于常规治疗(P>0.05)。
单独进行扁桃体切除术或类固醇治疗均不能提高 IgA 肾病患者的缓解率,而扁桃体切除术联合常规剂量类固醇或类固醇冲击治疗可提高缓解率,并具有良好的长期疗效。